Thrombophilia, hypofibrinolysis, the eNOS T-786C polymorphism, and multifocal osteonecrosis

Journal of Bone and Joint Surgery

Volumn 90, Issue 10, 2008, Pages 2220-2229

  Glueck, Charles J ^a   Freiberg, Richard A ^b   Boppana, Swapna ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PREDNISONE; PROTEIN S;

ADULT; ALCOHOLISM; ARTICLE; BLOOD CLOTTING DISORDER; BONE NECROSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HETEROZYGOSITY; HOMOCYSTINURIA; HUMAN; HYPOFIBRINOLYSIS; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SAMPLE SIZE; SEROLOGY; STEROID THERAPY; THROMBOPHILIA;

EID: 53549110810     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.G.00616     Document Type: Article

References (71)

1. LaPorte DM, Mont MA, Mohan V, Jones LC, Hungerford DS. Multifocal osteonecrosis. J Rheumatol. 1998;25:1968-74.
2. Symptomatic multifocal osteonecrosis. A multicenter study. Collaborative Osteonecrosis Group. Clin Orthop Relat Res. 1999;369:312-26.
3. Kaneshiro Y, Oda Y, Iwakiri K, Masada T, Iwaki H, Hirota Y, Kondo K, Takaoka K. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther. 2006;80:396-402.
4. van Schaardenburg D, van den Brink HR, Wieringa HJ. [Short-term steroid therapy, sometimes with long-term sequelae]. Ned Tijdschr Geneeskd. 2001;145:1769-73. Dutch.
5. Jacobs B. Alcoholism-induced bone necrosis. N Y State J Med. 1992;92:334-8.
6. Kubo T, Tsuji H, Yamamoto T, Nakahara H, Nakagawa M, Hirasawa Y. Antithrombin III deficiency in a patient with multifocal osteonecrosis. Clin Orthop Relat Res. 2000;378:306-11.
7. Pierre-Jacques H, Glueck CJ, Mont MA, Hungerford DS. Familial heterozygous protein-S deficiency in a patient who had multifocal osteonecrosis. A case report. J Bone Joint Surg Am. 1997;79:1079-84.
8. Glueck CJ, Glueck HI, Mieczkowski L, Tracy T, Speirs J, Stroop D. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb Haemost. 1993;69:460-5.
9. Glueck CJ, Freiberg RA, Sieve L, Wang P. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005;435:164-70.
10. Glueck CJ, Freiberg RA, Wang P. Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head. Clin Orthop Relat Res. 2008;466:1034-40.
11. Jones JP Jr. Risk factors potentially activating intravascular coagulation and causing nontraumatic osteonecrosis. In: Urbaniak JR, Jones JP Jr, editors. Osteonecrosis: etiology, diagnosis, and treatment. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1997. p 89-97.
12. Gruppo R, Glueck CJ, Wall E, Roy D, Wang P. Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation. J Pediatr. 1998;132:885-8.
13. Jones LC, Mont MA, Le TB, Petri M, Hungerford DS, Wang P, Glueck CJ. Procoagulants and osteonecrosis. J Rheumatol. 2003;30:783-91.
14. Balasa VV, Gruppo RA, Glueck CJ, Wang P, Roy DR, Wall EJ, Mehlman CT, Crawford AH. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am. 2004;86:2642-7.
15. Koo KH, Kim R, Cho SH, Song HR, Lee G, Ko GH. Angiography, scintigraphy, intraosseous pressure, and histologic findings in high-risk osteonecrotic femoral heads with negative magnetic resonance images. Clin Orthop Relat Res. 1994;308:127-38.
16. Korompilias AV, Gilkeson GS, Ortel TL, Seaber AV, Urbaniak JR. Anticardiolipin antibodies and osteonecrosis of the femoral head. Clin Orthop Relat Res. 1997;345:174-80.
17. Korompilias AV, Ortel TL, Urbaniak JR. Coagulation abnormalities in patients with hip osteonecrosis. Orthop Clin North Am. 2004;35:265-71, vii.
18. Kutlar A, Kutlar F, Turker I, Tural C. The methylene tetrahydrofolate reductase (C677T) mutation as a potential risk factor for avascular necrosis in sickle cell disease. Hemoglobin. 2001;25:213-7.
19. Bjorkman A, Svensson PJ, Hillarp A, Burtscher IM, Runow A, Benoni G. Factor V Leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res. 2004;425:168-72.
20. Boss JH, Misselevich I. Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol. 2003;40:345-54.
21. Liu SL, Ho TC. The role of venous hypertension in the pathogenesis of Legg-Perthes disease. A clinical and experimental study. J Bone Joint Surg Am. 1991;73:194-200.
22. Norman D, Reis D, Zinman C, Misselevich I, Boss JH. Vascular deprivationinduced necrosis of the femoral head of the rat. An experimental model of avascular osteonecrosis in the skeletally immature individual or Legg-Perthes disease. Int J Exp Pathol. 1998;79:173-81.
23. Zalavras C, Dailiana Z, Elisaf M, Bairaktari E, Vlachogiannopoulos P, Katsaraki A, Malizos KN. Potential aetiological factors concerning the development of osteonecrosis of the femoral head. Eur J Clin Invest. 2000;30:215-21.
24. Zalavras CG, Vartholomatos G, Dokou E, Malizos KN. Genetic background of osteonecrosis: associated with thrombophilic mutations? Clin Orthop Relat Res. 2004;422:251-5.
25. Van Veldhuizen PJ, Neff J, Murphey MD, Bodensteiner D, Skikne BS. Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol. 1993;44:243-8.
26. Jones JP Jr. Fat embolism, intravascular coagulation, and osteonecrosis. Clin Orthop Relat Res. 1993;292:294-308.
27. Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol. 1997;24:654-62.
28. Nilsson IM, Krook H, Sternby NH, Soderberg E, Soderstrom N. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta Med Scand. 1961;169:323-37.
29. Eldridge J, Dilley A, Austin H, EL-Jamil M, Wolstein L, Doris J, Hooper WC, Meehan PL, Evatt B. The role of protein C, protein S, and resistance to activated protein C in Legg-Perthes disease. Pediatrics. 2001;107:1329-34.
30. Szepesi K, Posan E, Harsfalvi J, Ajzner E, Szucs G, Gaspar L, Csernatony Z, Udvardy M. The most severe forms of Perthes' disease associated with the homozygous Factor V Leiden mutation. J Bone Joint Surg Br. 2004;86:426-9.
31. Koo KH, Lee JS, Lee YJ, Kim KJ, Yoo JJ, Kim HJ. Endothelial nitric oxide synthase gene polymorphisms in patients with nontraumatic femoral head osteonecrosis. J Orthop Res. 2006;24:1722-8.
32. Glueck CJ, Freiberg RA, Oghene J, Fontaine RN, Wang P. Association between the T-786C eNOS polymorphism and idiopathic osteonecrosis of the head of the femur. J Bone Joint Surg Am. 2007;89:2460-8.
33. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32:94-124.
34. Ficat RP. Cortisone associated necrosis of bone. In: Hungerford D, editor. Ischemia and necrosis of bone. Baltimore: Williams and Wilkins; 1980. p 171-6.
35. McKee MD, Waddell JP, Kudo PA, Schemitsch EH, Richards RR. Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: a report of 15 cases. CMAJ. 2001;164:205-6.
36. Balasa VV, Gruppo RA, Glueck CJ, Stroop D, Becker A, Pillow A, Wang P. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. J Thromb Haemost. 1999;81:739-44.
37. Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001;386:19-33.
38. Glueck CJ, Fontaine RN, Gruppo R, Stroop D, Sieve-Smith L, Tracy T, Wang P. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res. 1999;366:133-46.
39. Glueck CJ, Iyengar S, Goldenberg N, Smith LS, Wang P. Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med. 2003;142:35-45.
40. Perry SL, Ortel TL. Clinical and laboratory evaluation of thrombophilia. Clin Chest Med. 2003;24:153-70.
41. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Ogawa H, Kugiyama K, Mizuno Y, Harada E, Nakamura S, Ito T, Saito Y, Miyamoto Y, Ogawa Y, Nakao K. T(-786) - > C mutation in the 59-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol. 2000;86:628-34.
42. Glueck CJ, Freiberg RA, Fontaine RN, Sieve-Smith L, Wang P. Anticoagulant therapy for osteonecrosis associated with heritable hypofibrinolysis and thrombophilia. Expert Opin Investig Drugs. 2001;10:1309-16.
43. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279-84.
44. Roach R, Miller D, Griffiths D. Multifocal osteonecrosis predominantly affecting the knees secondary to chronic alcohol ingestion: a case report and review. Acta Orthop Belg. 2006;72:234-6.
45. Jones LC, Mont MA, Le TB, Petri M, Hungerford DS, Wang P, Glueck CJ. Procoagulants and osteonecrosis. J Rheumatol. 2003;30:783-91.
46. Blanche P, Si-Larbi AG, Jouve P. Femoral head necrosis and hyperhomocysteinemia. J Rheumatol. 2001;28:1469.
47. Bonding P, Skriver E, Helin P, Qvortrup K. Destructive, granulating lesion in the temporal bone after elevated plasma homocysteine. Otol Neurotol. 2004;25:610-5.
48. Bank I, Libourel EJ, Middeldorp S, Hamulyak K, van Pampus EC, Koopman MM, Prins MH, van der Meer J, Buller HR. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. 2005;3:79-84.
49. Lavigne G, Mercier E, Quere I, Dauzat M, Gris JC. Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. J Thromb Haemost. 2003;1:2134-9.
50. Legnani C, Cini M, Cosmi B, Poggi M, Boggian O, Palareti G. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica. 2004;89:1347-51.
51. Schambeck CM, Hinney K, Haubitz I, Mansouri Taleghani B, Wahler D, Keller F. Familial clustering of high factor VIII levels in patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2001;21:289-92.
52. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999;81:680-3.
53. Tripodi A. Issues concerning the laboratory investigation of inherited thrombophilia. Mol Diagn. 2005;9:181-6.
54. Glueck CJ, Freiberg RA, Wang P. Role of thrombosis in osteonecrosis. Curr Hematol Rep. 2003;2:417-22.
55. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-7. Erratum in: N Engl J Med. 1999;341:298.
56. Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, Ozoux ML, Pensyl CE, Bigonzi F. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61:163-70.
57. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet. 1992;340:873-6.
58. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332:1661-5.
59. Schulman S. Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings. J Intern Med. 1999;245:399-403.
60. Thaler HW, Roller RE, Greiner N, Sim E, Korninger C. Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. J Trauma. 2001;51:518-21.
61. Arlet J, Ficat P. [Diagnosis of primary femur head osteonecrosis at stage 1 (preradiologic stage)]. Rev Chir Orthop Reparatrice Appar Mot. 1968;54:637-48. French.
62. Glueck CJ, Freiberg RA, Wang P. Detecting thrombophilia, hypofibrinolysis, and reduced nitric oxide production in osteonecrosis. Seminars in Arthroplasty. 2007;18:184-91.
63. Hofmann S, Mazieres B. [Osteonecrosis: natural course and conservative therapy]. Orthopade. 2000;29:403-10. German.
64. Koo KH, Kim R, Ko GH, Song HR, Jeong ST, Cho SH. Preventing collapse in early osteonecrosis of the femoral head. A randomised clinical trial of core decompression. J Bone Joint Surg Br. 1995;77:870-4.
65. Stulberg BN, Davis AW, Bauer TW, Levine M, Easley K. Osteonecrosis of the femoral head. A prospective randomized treatment protocol. Clin Orthop Relat Res. 1991;268:140-51.
66. Kagemann G, Sies H, Schnorr O. Limited availability of L-arginine increases DNA-binding activity of NF-kappaB and contributes to regulation of iNOS expression. J Mol Med. 2007;85:723-32.
67. Bode-Böger SM. Effect of L-arginine supplementation on NO production in man. Eur J Clin Pharmacol. 2006;62 Suppl 1:91-9.
68. Böger RH, Bode-Böger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol. 2001;41:79-99.
69. MacKenzie A, Wadsworth RM. Extracellular L-arginine is required for optimal NO synthesis by eNOS and iNOS in the rat mesenteric artery wall. Br J Pharmacol. 2003;139:1487-97.
70. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis. 1997;129:261-9.
71. Glueck CJ, Haque M, Winarska M, Dharashivkar S, Fontaine RN, Zhu B, Wang P. Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: a pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease. Clin Appl Thromb Hemost. 2006;12:427-39.